Nanjing Hicin Pharmaceutical Co Ltd - Asset Resilience Ratio
Nanjing Hicin Pharmaceutical Co Ltd (300584) has an Asset Resilience Ratio of 0.08% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see balance sheet size of Nanjing Hicin Pharmaceutical Co Ltd.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2020)
This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Nanjing Hicin Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nanjing Hicin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See defensive interval ratio of Nanjing Hicin Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.00 Million | 0.08% |
| Total Liquid Assets | CN¥1.00 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Nanjing Hicin Pharmaceutical Co Ltd maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nanjing Hicin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanjing Hicin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Livzon Pharmaceutical Group Inc
SHE:000513 |
Drug Manufacturers - Specialty & Generic | 2.93% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
Annual Asset Resilience Ratio for Nanjing Hicin Pharmaceutical Co Ltd (2017–2020)
The table below shows the annual Asset Resilience Ratio data for Nanjing Hicin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 1.10% | CN¥10.00 Million ≈ $1.46 Million |
CN¥906.52 Million ≈ $132.65 Million |
-1.41pp |
| 2018-12-31 | 2.52% | CN¥20.00 Million ≈ $2.93 Million |
CN¥794.19 Million ≈ $116.21 Million |
-16.62pp |
| 2017-12-31 | 19.14% | CN¥121.00 Million ≈ $17.71 Million |
CN¥632.30 Million ≈ $92.53 Million |
-- |
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more